Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 10

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 10
---
 deer tick bites) in the United States each year.9 Approximately 650 of these cases are hospitalizations, a smaller           
 fraction of which represents immunosuppressed individuals.10 Symptomatic babesiosis is usually treated with a minimum                  
 ten day course of atovaquone and azithromycin which is extended to six weeks in the immunosuppressed, who may also experience relapses 
 requiring multiple hospitalizations.11 This is much longer than equivalent serious parasitic diseases such as malaria                  
 where the goal is a three-day regimen. In a recently published case series Tafenoquine in combination with standard of care cured      
 80% of immunosuppressed patients with relapsing babesiosis and the investigators stated in a press release that “Tafenoquine           
 is going to make a huge difference, I think, in people who are severely immunocompromised.” 12                                         |

| ● | Prevention                                                                                         
 of Tick-Borne Diseases. Post-exposure prophylaxis or early treatment with, respectively,           
 a single dose or several week regimen of doxycycline following a tick-bite is a recognized         
 indication to prevent the complications of Lyme disease. There may be more than 400,000 such       
 tick bites in the United States requiring medical treatment each year. This estimate is based      
 on the observation that approximately 50,000 tick bites are treated in U.S. hospital emergency     
 rooms each year; however, this calculation represents only about 12% of actual treated tick        
 bites based on observations from comparable ex-U.S health systems.13 Unlike Lyme                   
 disease, there is no characteristic rash associated with early infection and no reliable           
 diagnostic tests. Thus, an individual bitten by a tick cannot know whether they have also          
 been infected with babesiosis. It is likely that a drug proven to be effective for this indication 
 for babesiosis would also be used in conjunction with Lyme prophylaxis.                            |

| ● | Veterinary Indications. Based                                                                                                        
 on estimates from industry experts, there may be somewhere between several hundred and several thousand cases of canine babesiosis   
 each year in the United States, and thousands more globally. Currently, standard of care treatment for babesiosis in dogs is         
 a ten-day course of atovaquone and azithromycin, which costs about $1,350 out of pocket. A treatment course of Tafenoquine mirroring 
 the human prophylactic dose in dogs might cost < $300, offering a compelling alternative to standard of care. The